Project Grant R21AI176445
- Federal Grant Award Summary The National Institute of Child Health and Human Development (NICHD) awarded a Project Grant of $422,916 under the Child Health and Human Development Extramural Research program (CFDA 93.865) to The Research Foundation For The State University Of New York, doing business as RF-SUNY at the University at Albany, effective August 1, 2025, with completion targeted for July 31, 2027. This research initiative investigates the functional consequences of inosine...
- This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...
- This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $158,750.00 to the University of Texas at Austin to conduct research on the function of the CACNA2D4 gene and its role in inherited retinal dystrophies. The overarching goal is to gain insight into the pathophysiological mechanisms of CACNA2D4-associated inherited retinal disorders by elucidating the structure-function relationships of the A2D-4 protein, which is...
- This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to uncover the structural and molecular mechanisms underlying calcium (Ca2+) signaling at contact sites between the endoplasmic reticulum (ER) and mitochondria in neurons. The research aims to utilize cutting-edge cryogenic electron tomography techniques to...
- This federal Project Grant award of $158,500 from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 aims to evaluate the therapeutic potential of gene replacement for SCYL1 deficiency syndrome. The award supports the development of two mouse models to enable the inducible restoration of SCYL1 gene expression, which is mutated in this rare, autosomal recessive, pediatric, multisystem disorder. The project seeks to recapitulate the phenotypic changes seen in humans...
- Trustees of Tufts College, doing business as Tufts University School of Medicine, received a $453,750 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The funding will support research to define the potential of gene therapy to correct motor disabilities associated with CTNNB1 syndrome, a rare genetic disorder characterized by intellectual...
- Federal Grant Award Summary Boston Children's Hospital received a $221,050 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective July 1, 2025, through January 2, 2028. The award supports investigator-initiated research to advance understanding of neuronal primary cilia dysfunction in Tuberous Sclerosis Complex (TSC), a rare genetic disorder...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded Emory University a $430,375 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to study disease-associated mutations and ligand activation of the adhesion G protein-coupled receptor ADGRB2. The key objectives are to: Investigate newly identified patient mutations in the ADGRB2 gene that are associated with spastic paraparesis and other neurological symptoms,...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $160,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports research to investigate the epigenetic mechanisms underlying neurodevelopmental defects in Menke-Hennekam Syndrome, a rare genetic disorder caused by mutations in the EP300 gene. The project aims to (1) identify maturation and...
- This federal Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to study the relationship between mitochondrial dysfunction and the impact of non-syndromic autism spectrum disorder (ASD)-related risk genes on neuronal structure and function. The $253,500 award, provided from April 2025 to March 2027, will support the development of...
THE IMPACT OF ITPR3 MUTATIONS ON IMMUNITY - PROJECT SUMMARY THE INOSITOL TRISPHOSPHATE RECEPTORS (ITPR1, ITPR2, ITPR3) ARE PRESENT IN THE ENDOPLASMIC RETICULUM, FORMING HOMO- OR HETERO- TETRAMERIC COMPLEXES TO CONTROL CALCIUM RELEASE. UPON BINDING TO THE SECOND MESSENGER, INOSITOL 1,4,5 TRISPHOSPHATE (IP3), THE ITPR CONTROLLED RELEASE OF CALCIUM CONTROLS DIFFERENTIATION, PROLIFERATION, AND DEATH PROCESSES FOR EVERY CELL TYPE IN THE BODY. WE IDENTIFIED THE SAME SINGLE ALLELIC MUTATION IN THE INOSITOL TRIS PHOSPHATE RECEPTOR TYPE 3 (ITPR3) IN TWO UNRELATED CHILDREN. THE MISSENSE MUTATION CREATES A P.ARG2524CYS AMINO ACID SUBSTITUTION WITHIN THE CALCIUM CHANNEL. THESE CHILDREN HAVE IMMUNODEFICIENCY, CHARCOT-MARIE TOOTH DISEASE AND PARTIAL TO COMPLETE ANHIDROSIS. WHILE AUTOSOMAL RECESSIVE ITPR3 MUTATIONS CAUSE ONE FORM OF CMT SYNDROME, IMMUNE SYSTEM PROBLEMS AND SWEATING DEFECTS ARE NOT NORMALLY SEEN. IN FACT, MOST SINGLE ALLELIC MUTATIONS IN ITPR3 ARE BENIGN DUE TO COMPENSATORY FUNCTIONS BY ITPR1 AND ITPR2. TO UNDERSTAND THE BASIS FOR THE MORE WIDESPREAD CLINICAL PRESENTATION OUR TWO PATIENTS WITH THE SINGLE ALLELIC P.R2524C VARIANT, AS WELL AS AN EXPANDING NUMBER BEING REPORTED ELSEWHERE, WE GENOCOPIED THE MUTATION IN MICE. OUR PRELIMINARY FINDINGS SUGGEST THIS ITPR3 P.R2524C VARIANT FORMS A CELL-TYPE SPECIFIC DOMINANT NEGATIVE. IN THE CURRENT PROPOSAL, WE WILL DETERMINE THE IMPACT OF THIS ITPR3 MUTATION ON CELL SIGNALING IN THE IMMUNE, NEURONAL, AND ECCRINE SYSTEMS. A CHARACTERIZATION OF THE T AND B CELLS OF THE ADAPTATIVE IMMUNE SYSTEM WILL BE DONE WITH A COMBINATION OF FUNCTIONAL ASSAYS AND SIGNALING STUDIES. ADDITIONALLY, A CHARACTERIZATION OF THE SCHWANN CELLS OF THE PERIPHERAL NERVOUS SYSTEM AND ECCRINE CELLS WILL BE UNDERTAKEN. THE STUDIES WILL BE COMPLEMENTED WITH KNOCKDOWN APPROACHES USING SHRNA TECHNOLOGIES TO DETERMINE IF FUNCTIONALITY CAN BE RESTORED BY SELECTIVELY TARGETING ITPR3.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $205.0k | 4/11/25 | ||
| Not listed | $24.6k | 9/11/24 | ||
| Not listed | $24.6k | 9/11/24 | ||
| Not listed | $221.4k | 6/21/24 | ||
| Not listed | $221.4k | 6/21/24 |